What is Atea Pharmaceuticals?
Headquartered in Boston, Massachusetts, Atea Pharmaceuticals is a clinical-stage biopharmaceutical firm dedicated to the discovery, development, and commercialization of oral antiviral therapeutics. The company's research focus is centered on high-impact viral infections, with a lead product candidate, AT-527, currently undergoing Phase 3 clinical evaluation for COVID-19. Furthermore, Atea is actively developing bemnifosbuvir in combination with ruzasvir for the treatment of hepatitis C, demonstrating a robust and diversified R&D portfolio. By integrating advanced molecular science with strategic licensing agreements, such as its partnership with MSD International GmbH, Atea maintains a competitive edge in the global biopharmaceutical landscape.
How much funding has Atea Pharmaceuticals raised?
Atea Pharmaceuticals has raised a total of $591M across 6 funding rounds:
Series A
$20M
Unspecified
$20.8M
Unspecified
$27.6M
Series B
$7.6M
Series D
$215M
Stock Offering
$300M
Series A (2014): $20M, investors not publicly disclosed
Unspecified (2016): $20.8M, investors not publicly disclosed
Unspecified (2018): $27.6M, investors not publicly disclosed
Series B (2019): $7.6M, investors not publicly disclosed
Series D (2020): $215M backed by Redmile Group, RA Capital Management , LLC, Morningside Ventures, Omega Funds, Bain Capital LP, T. Rowe Price Associates, Adage Capital Management, Ally Bridge Group, Rock Springs Capital, Perceptive Advisors, Cormorant Asset Management, and Sectoral Asset Management
Stock Issuance/Offering (2020): $300M with participation from Undisclosed
Key Investors in Atea Pharmaceuticals
Redmile Group
Redmile Group LLC is a specialized venture capital and private equity firm that focuses on high-growth opportunities within the healthcare and life sciences sectors.
T. Rowe Price Associates
A global investment management firm that provides equity and fixed income mutual funds to institutional and individual investors, often participating in large-scale biotech financing.
Ally Bridge Group
A global healthcare investment management firm specializing in high-impact life science innovation, managing significant transactions to support companies throughout their clinical lifecycle.
What's next for Atea Pharmaceuticals?
Looking ahead, Atea Pharmaceuticals is positioned to leverage its substantial capital reserves to navigate the complexities of late-stage clinical trials and regulatory approval processes. The strategic focus remains on the successful execution of the SUNRISE-3 trial and the continued advancement of its protease inhibitor programs. As the company transitions from a development-heavy phase toward potential commercialization, the emphasis will likely shift toward scaling manufacturing capabilities and establishing market access. With a strong foundation of institutional backing, Atea is well-equipped to address unmet medical needs and deliver long-term value in the rapidly evolving antiviral therapeutic market.
See full Atea Pharmaceuticals company page
